Product Description
Targeting TSLP and IL-11 IgG1-type Bispecific Antibody. (Sourced from: https://clinicaltrials.gov/study/NCT06612970)
Mechanisms of Action: TSLP Inhibitor,IL11 Inhibitor
Novel Mechanism: Yes
Modality: Bispecific Antibody
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Huaota Biopharmaceutical
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|